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Abstract: We have recently shown that the extracellular matrix molecule hyaluronan (HA) plays
a role in the development of ovarian cancer chemoresistance. This present study determined
if HA production is increased in chemotherapy-resistant ovarian cancers and if the HA inhibitor
4-methylubelliferone (4-MU) can overcome chemoresistance to the chemotherapeutic drug carboplatin
(CBP) and inhibit spheroid formation and the expression of cancer stem cell (CSC) markers.
We additionally assessed whether 4-MU could inhibit in vivo invasion of chemoresistant primary
ovarian cancer cells in the chicken embryo chorioallantoic membrane (CAM) assay. The expression
of the HA synthases HAS2 and HAS3 was significantly increased in chemoresistant compared
to chemosensitive primary ovarian cancer cells isolated from patient ascites. 4-MU significantly
inhibited HA production, cell survival, and spheroid formation of chemoresistant serous ovarian
cancer cells. In combination with CBP, 4-MU treatment significantly decreased ovarian cancer cell
survival and increased apoptosis of chemoresistant primary cells compared to CBP alone. 4-MU
significantly reduced spheroid formation, expression of CSC markers ALDH1A1 and ABCG2 in
primary cell spheroid cultures, and ALDH1 immunostaining in patient-derived tissue explant assays
following treatment with CBP. Furthermore, 4-MU was very effective at inhibiting in vivo invasion of
chemoresistant primary cells in CAM assays. Inhibition of HA is therefore a promising new strategy
to overcome chemoresistance and to improve ovarian cancer survival.
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1. Introduction
Ovarian cancer is the most lethal gynaecological cancer and the fifth most common cause of
cancer-related death among Western women [1]. Current clinical practice for advanced ovarian cancer
consists of de-bulking surgery followed by combined platinum and taxane-based chemotherapy. High
grade serous ovarian cancers make up nearly 70% of ovarian cancers and are characterized by high
initial chemosensitivity. However, 75% of patients relapse after treatment and subsequently develop
resistance to platinum-based drugs [2]. Chemotherapy resistance is the major clinical challenge in
ovarian cancer treatment and strategies that can overcome chemoresistance will greatly improve
patient survival.
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Chemoresistance is multifactorial involving both tumour and drug-related factors, but recent
data also suggest a critical role of the tumour microenvironment [3]. Our recent studies focussing on
the tumour microenvironment linked chemoresistance to the production of the extracellular matrix
(ECM) molecule hyaluronan (HA), which is known to play an important role in cancer progression and
metastasis [4]. HA is a large polysaccharide which is assembled into pericellular and ECM matrices
in many tissues [5]. HA levels are regulated by three HA synthases (HAS1–HAS3) which synthesize
HA from glycolytic metabolites UDP-D-glucuronic acid (GLcUA) and UDP-N-acetylglucosamine
(GlcAc) [6]. HA levels in mammalians are also controlled by three HA-degrading hyaluronidases
(HYAL1–3) which produce low molecular weight HA fragments in the ECM [7]. HA plays a role in
various cell functions such as adhesion, motility, and differentiation and has been implicated in playing
a key role in cancer metastasis [5,8] with HA levels correlating with the degree of invasiveness and
metastatic potential of ovarian cancers [9].
HA treatment can reduce the ability of chemotherapy drugs to cause cancer cell death in various
cancer cell lines [10–12]. We recently investigated the ability of HA to block the growth inhibitory
effects of the cytotoxic drug carboplatin (CBP) in a range of ovarian cancer cells [13]. We found that
adding HA to CBP-treated cells only increased survival of ovarian cancer cell lines expressing the
HA receptor CD44 [13]. The increased cell survival observed with concurrent CBP and HA treatment
was reversed by blocking CD44-HA interactions by either the addition of HA oligomers (chains of
6–10 saccharides), or a neutralising CD44 antibody [13].
A potent inhibitor of HA synthesis is 4-methylumbelliferone (4-MU). 4-MU reduces the cellular
content of UDP-GlcUA and also inhibits synthesis of HA synthase enzymes [14]. 4-MU (also known as
hymecromone) is a modified coumarin of plant origin which has been used in patients in Asia and
Europe for the treatment of hepatobiliary disease because of its choleretic and biliary antispasmodic
activity [15]. 4-MU is effective at blocking growth and metastasis of several different cancers including
pancreatic, prostate, breast and liver cancers in animal studies [16–20]. Limited studies to date have
investigated the effects of 4-MU on ovarian cancer cells.
This study assessed if HA production is increased in patients developing chemoresistant
disease and in chemoresistant primary serous ovarian cancer cells compared to chemosensitive
cells. We determined whether the HA inhibitor 4-MU could increase the cytotoxic effect of CBP. We also
evaluated whether 4-MU could inhibit spheroid formation and expression of cancer stem cell (CSC)
markers in spheroids and a patient-derived explant tissue assay [21], as well as in vivo invasion of
chemoresistant primary ovarian cancer cells using the chicken embryo chorioallantoic membrane
(CAM) assay [22].
2. Results
2.1. HA Serum Levels Are Elevated in Patients with Chemoresistant Disease
Serum HA levels are significantly elevated in serous ovarian cancer patients that develop
chemoresistant disease (median 123.2, range 58.6–252 ng/mL) compared to levels at diagnosis
(median 21.3, range 10.5–111.7 ng/mL) (Figure 1a, n = 9, p = 0.0039, Wilcoxon pair test). In contrast,
serum HA levels were not significantly elevated in patients who relapsed but continued to respond to
chemotherapy treatment (Figure 1b, n = 7, p = 0.219, Wilcoxon pair test). HA staining in matching
tissues from two patients at diagnosis confirms increased production of HA in cancer cells and the
peritumoral stroma following relapse with chemotherapy-resistant disease (Figure S1).
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Figure 1. Serum hyaluronan (HA) is elevated in patients with chemoresistant disease. (a) HA serum 
levels (ng/mL) in serous ovarian cancer patients at initial diagnosis and following relapse with 
chemoresistant disease (n = 9). * significantly different from levels at diagnosis (p = 0.0039, Wilcoxon 
pair test). (b). HA serum levels (ng/mL) in serous ovarian cancer patients at initial diagnosis and 
following relapse with chemosensitive disease (n = 7, p = 0.219, Wilcoxon pair test). 
2.2. HA Production Is Increased in Serous Ovarian Cancer Cells Following Development of Chemotherapy 
Resistance 
We examined expression of HA synthases (HAS1, HAS2, and HAS3) and hyaluronidases 
(HYAL1, HYAL2) in primary serous ovarian cancer cells isolated from patient ascites and CBP-
resistant OV-90 cells. We found that HAS2 (Figure 2b) and HAS3 (Figure 2c) but not HAS1 (Figure 
2a) expression is significantly increased in primary serous ovarian cancer cells isolated from the 
ascites of patients with chemoresistant disease compared to patients with chemosensitive disease. 
HAS2 and HAS3 expression was also significantly increased in CBP-resistant OV-90 CBPR cells 
compared to parental cells (Figure 2b,c). HAS1 was not detected in any ovarian cancer cell lines 
examined. HYAL1 and HYAL2 expression was not different between the chemosensitive and 
chemoresistant primary ovarian cancer cells nor between CBP-resistant OV-90 cells compared to 
parental cells (Figure 2d,e). We also confirmed by HA ELISA that chemoresistant primary serous 
ovarian cancer cells had significantly higher levels of HA in the conditioned media compared to 
chemosensitive cells (Figure 2f). HA levels were also significantly increased in conditioned media 
from OV-90 CBPR cells compared to parental OV-90 cells (Figure 2f). 
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2.2. HA Production Is Increased in Serous Ovarian Cancer Cells Following Development of Chemotherapy
Resistance
We examined expression of HA synthases (HAS1, HAS2, and HAS3) and hyaluronidases (HYAL1,
HYAL2) in primary serous ovarian cancer cells isolated from patient ascites and CBP-resistant OV-90
cells. We found that HAS2 (Figure 2b) and HAS3 (Figure 2c) but not HAS1 (Figure 2a) expression
is significantly increased in primary serous ovarian cancer cells isolated from the ascites of patients
with chemoresistant disease compared to patients with chemosensitive disease. HAS2 and HAS3
expression was also significantly increased in CBP-resistant OV-90 CBPR cells compared to parental
cells (Figure 2b,c). HAS1 was not detected in any ovarian cancer cell lines examined. HYAL1 and
HYAL2 expression was not different between the chemosensitive and chemoresistant primary ovarian
cancer cells nor between CBP-resistant OV-90 cells compared to parental cells (Figure 2d,e). We also
confirmed by HA ELISA that chemoresistant primary serous ovarian cancer cells had significantly
higher levels of HA in the conditioned media compared to chemosensitive cells (Figure 2f). HA levels
were also significantly increased in conditioned media from OV-90 CBPR cells compared to parental
OV-90 cells (Figure 2f).
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HAS2 (p = 0.0218, Mann Whitney U test) and HAS3 (p = 0.0107, Mann Whitney U test) but not HAS1 
expression (p = 0.879, Mann Whitney U test) was significantly increased in chemoresistant cells 
compared to chemosensitive cells. **, HAS2 (p = 0.021, Student t test) and HAS3 (p <0.0001, Student t 
test) were significantly increased in OV-90 CBPR compared to parental cells. HYAL1 and HYAL2 
expression was not significantly different between the chemosensitive and chemoresistant primary 
cancer cells nor the OV-90 cell lines. The bars for the primary cells specify the median values in each 
group and are expressed as the mean fold change from RNA samples (n = 6–9) from three independent 
experiments. Data for OV-90 cells are expressed as the mean fold change ± SEM from 7–12 individual 
RNA samples from 2–3 independent experiments. (f) HA levels measured by ELISA assay in 
conditioned media. *, significantly increased in primary chemoresistant (n = 8) compared to 
chemosensitive (n = 10) serous ovarian cancer cells (p = 0.043, Mann Whitney U test). **, significantly 
increased in OV-90 CBPR conditioned media compared to parental cells (p = 0.0227, Mann Whitney 
U test). 
2.3. 4-MU Treatment Inhibits Survival of Chemoresistant Ovarian Cancer Cells 
We investigated whether 4-MU could inhibit the survival of ovarian cancer cells (as measured 
by cell viability with the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide, MTT assay) 
including primary chemosensitive and chemoresistant serous cancer cells derived from patient 
ascites and established ovarian cancer cell lines (OV-90, OV-90 CBPR, SKOV3) with varying 
sensitivity to CBP [13]. Established cell lines with CBP (half maximal inhibitory concentration, IC50 
≥180 µM (SKOV3, OV-90 CBPR) were classified as chemoresistant and primary cells from patient 
ascites were classified as chemosensitive or chemoresistant based on clinical response to 
chemotherapy. We initially tested a range of 4-MU concentrations (0–1 mM) and found that 1 mM, 
but not lower concentrations of 4-MU (0.1 mM, 0.5 mM), could significantly inhibit the survival of 
OV-90, SKOV3 cells, chemosensitive (P9), and chemoresistant (P13) primary serous ovarian cancer 
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(f) HA levels measured by ELISA assay in conditioned media. *, significantly increased in primary
chemoresistant (n = 8) compared to chemosensitive (n = 10) serous ovarian cancer cells (p = 0.043, Mann
Whitney U test). **, significantly increased in OV-90 CBPR conditioned media compared to parental
cells (p = 0.0227, Mann Whitney U test).
2.3. 4-MU Treatment Inhibits Survival of Chemoresistant Ovarian Cancer Cells
We investigated whether 4-MU could inhibit the survival of ovarian cancer cells (as measured
by cell viability with the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide, MTT assay)
including primary chemosensitive and chemoresistant serous cancer cells derived from patient ascites
and established ovarian cancer cell lines (OV-90, OV-90 CBPR, SKOV3) with varying sensitivity to
CBP [13]. Established cell lines with CBP (half maximal inhibitory concentration, IC50 ≥180 µM
(SKOV3, OV-90 CBPR) were classified as chemoresistant and primary cells from patient ascites were
classified as chemosensitive or chemoresistant based on clinical response to chemotherapy. We initially
tested a range of 4-MU concentrations (0–1 mM) and found that 1 mM, but not lower concentrations of
4-MU (0.1 mM, 0.5 mM), could significantly inhibit the survival of OV-90, SKOV3 cells, chemosensitive
(P9), and chemoresistant (P13) primary serous ovarian cancer cells (Figure S2). We used 1 mM
4-MU for all subsequent experiments. 4-MU (1 mM) significantly reduced the cell survival of both
chemosensitive (black bars, range 43–69% of control Figure 3a) and chemoresistant (grey bars, range
58–82% of control, Figure 3a) ovarian cancer cells. 4-MU was very effective at inhibiting HA production
in both chemosensitive (OV-90, P9) and chemoresistant ovarian cancer cells (SKOV3, OV-90 CBPR, P13,
Figure 3b). However, exogenous HA (222 kDa and 1110 kDa, 10 µg/mL) treatment could not reverse
the effects of 1 mM 4-MU in the MTT assays (Figure S3).
We assessed whether 4-MU could increase the cytotoxic effect of CBP in both chemosensitive and
chemoresistant ovarian cancer cells. In cell survival assays, OV-90 cells and chemosensitive primary
ovarian cancer cells exhibited a similar response to CBP (100 µM) or 4-MU (1 mM). Combined 4-MU
and CBP treatment did not further decrease ovarian cancer cell survival (Figure 3c,d). However,
combined CBP (100 µM) and 4-MU treatment (1 mM) significantly decreased survival of SKOV-3 cells
and chemoresistant primary serous ovarian cancer cells (n = 8) compared to CBP alone (Figure 3e,f).
Effects of 4-MU (1 mM) and/or CBP (100 µM) treatment on apoptosis were measured by using a caspase
3/7 cleavage assay in primary serous ovarian cancer cells. We showed that 4-MU alone and combined
CBP and 4-MU treatments increased the level of apoptosis in chemosensitive primary cells compared
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to control treatment (Figure 3g). In chemoresistant primary cells, combined CBP and 4-MU treatment
increased the level of apoptosis compared to cells treated with control media or CBP alone (Figure 3h).
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Figure 3. Effects of 4-methylubelliferone (4-MU) and carboplatin on ovarian cancer cell survival and
HA production. (a) Ovarian cancer cell survival following 72 h of 4-MU (1 mM) treatment. The black
and grey bars represent chemosensitive and chemoresistant cells, respectively. Data are expressed
as percentage of control, mean ± SEM from 2–3 independent experiments performed in triplicate.
*, significantly different from control media treatment (p < 0.05, independent t test). (b). Effect of 4-MU
(1 mM) 72 h on HA production in conditioned media measured by HA ELISA. Data are expressed as
ng/mL from 4–6 determinations. *, significantly different from control treatment (p < 0.05, independent
t test). Effect of 4-MU on survival of OV-90 (c), chemosensitive primary cells (n = 2) (d), SKOV3
(e), and chemoresistant primary cells (n = 8), (f) assessed by MTT assay. Cells were treated with
phosphate buffered saline (PBS), control, 4-MU (1 mM), carboplatin (CBP, 100 µM), and 4-MU (1 mM)
+ CBP (100 µM) for 72 h. Data are expressed as % of control from 2–5 independent experiments
performed in quadruplicate. Effects of 4-MU (1 mM) and/or CBP (100 µM) treatment on apoptosis
measured by caspase 3/7 cleavage in primary serous ovarian cancer cells. (g) chemosensitive (n = 3),
and (h) chemoresistant (n = 5) cells. (a–h) *, significantly different from control, **, significantly different
from CBP treatment, ***, significantly different from 4-MU treatment, (p < 0.05, one way ANOVA,
Tukey’s multiple comparisons test).
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2.4. 4-MU Inhibits Spheroid Formation and Stem Cell Marker Expression
4-MU treatment significantly reduced the area of spheroids formed by OV-90 (Figure 4a),
and chemoresistant primary ovarian cancer cells (Figure 4b). OV-90 cells exhibited a similar response
to CBP (100 µM) or 4-MU (1 mM) treatment alone and combined 4-MU and CBP treatment did not
further decrease OV-90 spheroid size (Figure 4a). CBP treatment had no effect on the spheroid area
of chemoresistant primary serous ovarian cancer cells. However, in combination with 4-MU (1 mM),
the spheroid area of chemoresistant cells was significantly reduced compared to CBP alone (Figure 4b).
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We showed by qRT-PCR that 4-MU treatment reduced expression of both HAS2 (Figure 5a)
and HAS3 (Figure 5b) in OV-90 spheroids and spheroids formed by primary chemoresistant cells.
Expression of CSC marker PROM1 was significantly reduced in OV-90 spheroids (Figure 5c). PROM1
was not expressed by the primary chemoresistant cell spheroids. ALDH1A1 (Figure 5d) and ABCG2
expression (Figure 5e) was significantly reduced in spheroid cultures from chemoresistant primary
cells following 4-MU treatment. CD44 expression in the spheroids was not affected by 4-MU treatment
(Figure 5f).
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2.5. ALDH1 Protein Expression is Increased Following Chemotherapy Treatment and Reduced by 4-MU
Treatment in Patient-Derived Explant Assays
We assessed ALDH1 immunostaining in serous ovarian cancer tissues from patient derived tissue
explant assays (n = 5). ALDH1 immunostaining (percentage positive area, % POS area) measured
by video image analysis was significantly increased following 48 h of treatment with CBP (100 µM)
compared to control tissues (Figure 6a). However, the increase in ALDH1 % POS area by CBP
treatment was not observed in tissues treated with both 4-MU (1 mM) and CBP (100 µM) (Figure 6a).
Representative examples of the ALDH1 immunostaining in ex vivo explant tissues treated with
control media, CBP, 4-MU, or combined 4-MU and CBP are shown in Figure 6b–e, respectively.
We also showed that ALDH1 protein expression is increased in serous ovarian cancer tissues following
chemotherapy and at relapse compared to the levels in chemonaïve tissues (Figure 6f). Increased
ALDH1 immunostaining is evident in the images of Figure 6h,j that are examples of tissues from
the same patient after chemotherapy treatment and recurrence, respectively, compared to matching
chemonaïve tissues obtained at time of diagnosis (Figure 6g,i).
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2.6. 4-MU Treatment Reduces In Vivo Invasion of Chemoresistant Ovarian Cancer Cells
We evaluated the effects of 4-MU treatment on chemoresistant primary serous ovarian cancer cell
invasion using the in vivo chick chorioallantoic membrane (CAM) assay. CD44 immunohistochemistry
was used to assess ovarian cancer cell invasion from the ectoderm into the mesoderm layer of the CAM.
Representative images of the cell invasion following treatment with control media, 4-MU (1 mM), CBP
(100 µM) and CBP + 4-MU are shown in Figure 7a–d. Quantitative analysis showed that 4-MU (1 mM)
alone or combined with CBP (100 µM) treatment significantly decreased invasion of chemoresistant
primary cells compared to control treatment (Figure 7e).
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3. Discussion
The major limitation to the successful treatment of serous ovarian cancer is the emergence of
chemotherapy resistance. The development of more effective therapies to overcome chemotherapy
resistance and improve survival is urgently required. In this study we found that the expression
of the HA synthases HAS2 and HAS3 was significantly increased in chemoresistant compared to
chemosensitive primary ovarian cancer cells isolated from patient ascites. 4-MU significantly inhibited
HA production, cell survival, and spheroid formation of chemoresistant serous ovarian cancer cells.
Furthermore, 4-MU was effective at inhibiting expression of CSC markers (ALDH1A1 and ABCG2) and
in vivo invasion of chemoresistant serous ovarian cells. Our findings indicate that 4-MU treatment is a
promising strategy to inhibit HA production and CSC activation and improve survival of patients with
serous ovarian cancer.
In a previous report we showed that serum HA levels are increased in patients following
chemotherapy and patients that develop recurrent disease [13]. In this current study using matched
serum samples at diagnosis and relapse, we demonstrated that HA serum levels are significantly
increased up to 5-fold in serous ovarian cancer patients that relapsed with chemoresistant disease but
not in patients that relapsed but continue to respond to chemotherapy treatment. We showed that HA
was increased in both the peritumoral stroma and serous ovarian cancer cells in matching tissues from
patients at diagnosis and following relapse with chemoresistant disease. We additionally showed that
expression of HAS2 and HAS3 but not HAS1 or hyaluronidases HYAL1 and HYAL2 were significantly
increased in chemoresistant compared to chemosensitive primary serous ovarian cancer cells. HAS2
and HAS3 were similarly increased in OV-90 CBP cells that acquired CBP resistance compared to
parental OV-90 cells. Recent studies have also shown that leukemic cell lines with increased HA
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production resist chemotherapy [23,24]. Together, these findings support the concept that HA plays an
important role in the development of acquired chemotherapy resistance.
A potential mechanism whereby HA mediates chemoresistance is via expression of ABC transporter
membrane proteins which decrease levels of chemotherapy drugs within cells [25]. Several studies
have demonstrated that HA-CD44 interactions mediate chemotherapy resistance by regulating the
expression and activity of ABC transporters which function as efflux pumps and interfere with
the intracellular accumulation and retention of chemotherapy drugs [11,26]. We have previously
demonstrated that HA can regulate the expression of multiple ABC transporters including ABCB3,
ABCC1, ABCC2, and ABCC3 and carboplatin treatment increased ABCC2 and HA in OVCAR-5 cells [13].
In breast cancer, overexpression of HAS2 was reported to stimulate ABCB1 expression through the PI3K
pathway, increasing resistance to doxorubicin [27]. It was found that 500-kDa HA stimulated ABCB1
expression via CD44 in breast cancer (MCF-7 cells), inducing resistance to doxorubicin, paclitaxel,
and etoposide [11,28]. HA (molecular weight not specified) also promoted expression of ABCC2 in
non-small cell lung cancer cells [29].
Our findings that 4-MU can inhibit HA production and cell survival and promote apoptosis of
serous ovarian cancer cells agrees with other cancer studies in the literature [16,30–37]. We have shown
in this study that 4-MU is effective at inhibiting HA production and survival of both chemosensitive
and chemoresistant primary serous ovarian cancer cells. However, in chemoresistant serous ovarian
cancer cells, combined 4-MU and CBP treatment was more effective at inhibiting cell survival compared
to CBP alone. These findings also concur with our recent studies using ex vivo tissue explant assays
demonstrating that combined 4-MU and CBP treatment significantly increased apoptosis and reduced
proliferation in ovarian cancer tissues from patients with chemoresistant disease [21].
To date there have been limited studies that have investigated effects of 4-MU on ovarian cancer
cells. Previous studies have shown 4-MU treatment inhibits HA production and spheroid formation by
HAC-2 ovarian clear cell carcinoma cells [38] and HAS3 expression by SKOV3 ovarian cancer cells [14].
Tamura et al. recently reported that 4-MU inhibited cell proliferation of HRA ovarian cancer cells
in vitro [18]. However, as HRA ovarian cancer cells were found to express very low levels of HAS2
and CD44, the in vitro effects of 4-MU in these cells may be via a mechanism other than HA-CD44
signaling [18]. Our findings that the addition of exogenous HA could not reverse the effects of 1 mM
4-MU in the MTT assays supports this finding that 4-MU may also have anti-tumour activity that is
not dependant on HA. The study by Lompardia et al. 2013 [23] found that co-treatment with 500 µM
4-MU and 30-fold higher levels of HA (300 µg/mL) partially reverted the effects of 4-MU in leukemic
K5652 and Kv563 cells. Whereas treatment with lower concentration of 4-MU (100 µM) and HA
300 µg/mL completely restored baseline conditions in the cell lines. The authors concluded that effects
of low concentrations of 4-MU could be restored by exogenous HA and but higher doses of 4-MU
may trigger anti-proliferative signals independent of HA. In another study Arai et al. 2011 also found
that exogenous HA (200 µg/mL) could not neutralize effects of 4-MU on osteosarcoma cells including
formation of cell matrix, or cell proliferation [31]. They concluded from this finding that HA may have
different biological activity if presented to cells as free exogenous HA or as endogenous cell-associated
HA. Keller et al. found that 4-MU reduced both versican and fibronectin in trabecular meshwork cells
of the eye [39] but the effects could not be reversed by the addition of exogenous high (1500 kDa) or
low (40 kDa) molecular weight HA (500 µg/mL) to the culture medium. They suggested that since
exogenous HA could not reverse effect of 4-MU, only de novo synthesized HA altered versican and
fibronectin levels. It is likely that 4-MU may affect the synthesis and organization of other ECM
components to mediate its anti-proliferative effects on ovarian cancer cells.
The stemness and expansion of CSCs are thought to be highly influenced by changes in
the microenvironment and recent studies have highlighted a key role for HA in regulating CSC
populations [40,41]. Excessive HA production allows breast cancer cells to revert to a stem cell state via
the up-regulation of genes involved in regulating epithelial-mesenchymal transition [41]. HA has also
been shown to promote the formation of CSC populations in breast cancer [41] and glioblastoma cell
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lines [42]. Additionally, HA activates genes associated with stemness in embryogenesis and interacts
with CSCs to enhance stemness and therapy resistance [43]. Shiina et al. showed that molecular weight
of HA was important in promoting and maintaining stemness of CSCs in the head and neck cancer cell
line HSC-3 [44]. It was found that 200 kDa HA significantly promoted expression of cancer stem cell
genes, spheroid formation, and cisplatin resistance in ALDHhigh CD44v3high HSC-3 cells compared
to 5, 20, and 700 kDa HA [44]. Previous studies by Okuda et al. 2012 showed that 4-MU treatment
reduced HA matrix produced from CSCs isolated from MDA-MB231 cells overexpressing HAS2 [40].
Studies by Hiraga et al. 2013 and Chanmee et al. 2014 also found that 3D growth of breast cancer
cells was inhibited by 4-MU in a dose-dependent manner [41,45]. In this study we found that 4-MU
inhibited spheroid formation of both chemosensitive and chemoresistant serous ovarian cancer cells.
Furthermore, we showed that 4-MU inhibited expression of HAS2, HAS3 and CSC markers (ALDHA1
and ABCG2) in a 3D-spheroid culture of chemoresistant primary serous ovarian cancer cells. However,
the expression of other CSC markers identified in serous ovarian cancer cells [46] including PROM1
(CD133) and CD44 were not affected by 4-MU treatment in spheroids formed by the primary serous
ovarian cancer cells. A recent study has shown that 4-MU treatment significantly reduced expression
of CD44, CD133, CD90 and EpCAM in hepatic carcinoma cells in vitro [47].
Several ovarian cancer studies reported CSC marker expression to be increased following
chemotherapy [48–53]. We found that ALDH1 protein levels were significantly increased in cultured
explant tissues by CBP alone and this could be prevented by treatment with 4-MU. We also observed
increased ALDH1 positivity in serous ovarian cancer tissues obtained from patients that had received
neoadjuvant chemotherapy or had relapsed compared to chemonaïve tissues from patients who
had not received chemotherapy. In agreement with these findings, previous studies also found that
ALDH1 expression and activity was significantly higher in taxane- and platinum-resistant ovarian
cancer cells [50,51]. ALDH1-positive ovarian cancer cells were also enriched in residual A2780 tumour
xenografts after platinum therapy [52] and in patients that had received neo-adjuvant chemotherapy
treatment [53].
We demonstrated that 4-MU treatment inhibits the in vivo invasion of chemoresistant primary
serous ovarian cancer cells using the CAM assay. To the best of our knowledge this is the first study
to assess cell invasion of primary ovarian cancer cells in vivo using the CAM model. The inhibitory
effects on serous ovarian cancer cell invasion concur with previous in vitro [14,31,32,35–37,40,54,55]
and in vivo [17,30–32,35,36,40,55–57] studies investigating the anti-tumour effect of 4-MU. The only
ovarian cancer study to date investigating effects of 4-MU on motility and invasion found no effect
of 4-MU, either on HRA ovarian cancer cell migration nor invasion in vitro, but reported that 4-MU
treatment inhibited HRA tumour growth and metastasis in a rat model in vivo [18]. It is likely that
the tumour inhibitory effects of 4-MU in vivo may be mediated by inhibiting HA in the tumour
microenvironment as HRA ovarian cancer cells expressed low levels of HAS2 and HAS3 [18].
4. Materials and Methods
4.1. Cell Line Culture
The human ovarian cancer cell lines SKOV-3 and OV-90 were purchased from American Type
Culture Collection (ATCC, Manassas, VA, USA) and authenticated by a short tandem repeat (STR) DNA
profile in 2016. All cell lines were grown in RPMI 1640 media (cat no. R8758, Sigma Aldrich, St. Louis,
MO, USA) and cultured with 10% foetal bovine serum (Sigma Aldrich) and maintained at 37 ◦C in an
environment of 5% CO2. OV-90 cells were made resistant to CBP following treatment with 6–8 cycles
of CBP (50 µM, Accord Healthcare Pty Ltd, Melbourne, VIC, Australia) [58]. The OV-90 CBPR cells
exhibited an IC50 to CBP that was two-fold higher than that for the parental cells (data not shown).
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4.2. Primary Cell Isolation
Primary ovarian cancer cells were derived from ascites collected from advanced stage ovarian
cancer patients prior to chemotherapy treatment (n = 9) and following the development of
chemoresistant recurrent disease (n = 11) with approval of the Royal Adelaide Hospital Human
Ethics Committee as described previously [58]. All primary cells were grown in Advanced RPMI
1640 medium (cat no. 12633-020, Life Technologies, Mulgrave, VIC, Australia) supplemented with
4 mM L-glutamine, 10% FBS (Sigma Aldrich, St Louis, MO, USA), and antibiotics (100 U penicillin G,
100 µg/mL streptomycin sulfate, and 100 µg/mL amphotericin B, Sigma Aldrich). The epithelial
nature of the primary ovarian cancer cells was confirmed by cytokeratin immunocytostaining [59].
The clinicopathological characteristics of the patients used to isolate the primary cells are shown in
Table S1. Patient response to adjuvant chemotherapy was recorded after six months of treatment.
Patients were classified as chemosensitive if they exhibited a complete response and did not progress
within 6 months after completing the chemotherapy treatment. Patients that relapsed were classified
as chemoresistant when they longer responded to chemotherapy treatment.
4.3. HA Detection
An HA ELISA kit (cat no. DY3614, R&D Systems) was used to determine the concentration of HA
in serum samples or conditioned media samples as per manufacturer’s instructions [13]. HA in tissues
was detected as described previously [13]. HA staining was measured by video image analysis (VIA,
VideoPro 32; Leading Edge P/L, Marion, SA, Australia) as described previously [60]. Colour images
from contiguous fields for each tissue core were collected at a magnification of×400. VIA measurements
included the DAB stained area (i.e., positively stained area in pixel units) and the total tumour area
examined (i.e., positively and negatively stained area in pixel units), for each field, were used to derive
the % POS area. The clinicopathological characteristics of the relapsed patients used for HA serum
measurements are shown in Table S2.
4.4. Cell Survival Assays
Ovarian cancer cells were plated at 5000 cells/well in 96-well plates in respective growth media.
After 24 h, cells were treated with control media, 4-MU (1 mM, cat no. M1508, Sigma Aldrich), CBP
(100 µM, Accord Healthcare Pty Ltd) or 4-MU (1 mM) + CBP (100 µM) for 72 h. This concentration of
4-MU has been shown to inhibit HA production by 60 to 80% in primary ovarian cancer cells (data not
shown). 4-MU was supplemented in the culture media every 24 h. Cell survival was calculated by
MTT assay as per the manufacturer’s instructions (Sigma Aldrich) [13].
4.5. Apoptosis Assays
Primary ovarian cancer cells were plated at 10,000 cells/well in 96-well plates in growth media.
After 24 h, cells were treated with control media, 4-MU (1 mM), CBP (100 µM), or 4-MU (1 mM) +
CBP (100 µM) for 72 h. Cell apoptosis by caspase 3/7 cleavage was measured using Caspase Glo 3/7
assay (Promega, Madison, WI, USA) as per manufacturer’s instructions. Luminescence endpoint was
measured using a Synergy H1 plate reader (BioTek Instrument Inc. Winooski, VT, USA).
4.6. Spheroid Assays
Primary ovarian cancer and OV-90 cells (2.5× 105 cells/well) were plated on poly-HEMA (30 mg/mL
in 95% ethanol, cat no. P3932, Sigma Aldrich) coated 24-well culture plates in RPMI containing 10%
FBS. Following 24 h cells were treated with control media or 4-MU (1 mM), CBP (100 µM), or 4-MU
(1 mM) + CBP (100 µM). Spheroid formation was observed over four days. Spheroid formation was
assessed in images taken using a light microscope EVOS® FL Imaging System (Life Technologies)
using a 4× objective. The area (µm2) of spheroids greater than 150 µm in length (n = 5 images) was
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determined for each of the treatment groups using Image J32 software, (Image J I.50i, National Institute
Health, Bethesda, MD, USA).
4.7. Quantitative RT-PCR
Primary ovarian cancer cells were plated at 30000 cells/well in 96-well plates and cultured for
24 h. RNA was extracted and reverse-transcribed with the TaqMan® Gene expression Cells-to-CT kit
(Applied Biosystems, Waltham, MA USA), according to manufacturer’s instructions. For spheroid
cultures, RNA was isolated using the mirVana miRNA Isolation Kit (AM1560, Thermofisher, Waltham,
MA USA), as per the manufacturer’s instructions. RNA from spheroid culture was quantified using
NanoDrop (Thermofisher), and 20 ng were added in complementary DNA cDNA synthesis reactions
using TaqMan® Gene expression Cells-to-CT kit. qRT-PCR reactions were performed on triplicate
cDNA samples using TaqMan® primer sets in Table S3 using Quantstudio 12 K flex real time PCR
machine (Applied Biosystems) as described [58]. CT values were normalised to the house keeping
gene β-actin and calibrator using the 2−∆∆CT method.
4.8. ALDH1 Immunohistochemistry
Formalin fixed serous ovarian cancer tissue sections were obtained from ex vivo tissue explant
assays (n = 5) treated for 48 h with control media, 4-MU (1 mM), CBP (100 µM) or a combination of 4-MU
(1 mM) and carboplatin (100 µM) [21]. Tissue from chemotherapy-naïve serous ovarian cancer patients
at surgery (n = 15), after receiving neoadjuvant chemotherapy (n = 20) and at relapse (n = 5), were
collected with approval from the Royal Adelaide Hospital Human Ethics Committee after informed
consent. The clinicopathological characteristics of the patients used to for ex-vivo tissue explant assays
and patient cohort used for ALDH1 immunohistochemistry are shown in Tables S4 and S5 respectively.
All tissue sections (5 µm) underwent microwave antigen retrieval as described previously [58] and
incubated overnight with ALDH1 mouse monoclonal antibody (1/400, clone 44/ALDH1, BD Biosciences)
in blocking buffer (5% normal goat serum) at 4 ◦C. Visualization of immunoreactivity was achieved using
biotinylated anti-mouse immunoglobulins, streptavidin-peroxidase conjugate and diaminobenzidine
substrate as described previously [58]. Negative controls included tissues incubated with no primary
antibody or with mouse immunoglobulins. Slides were digitally scanned using the NanoZoomer Digital
Pathology System (Hamamatsu Photonics, Hamamatsu, SZK, Japan) and images were collected using
NDP view imaging software (NDP scan software v2.2, Hamamatsu Photonics). ALDH1 immunostaining
was measured by VIA as for HA described previously [60].
4.9. CAM In Vivo Invasion Assays
Fertilized white leghorn chicken eggs were obtained from Hi-Chick, South Australia, Australia.
Eggs were incubated in a MultiQuip Incubator at 37 ◦C with 60% humidity. Ethics approval was
obtained by the University of Adelaide Animal Ethics Committee (RAH protocol No: 140101 and
R20181215). Primary serous ovarian cancer cells derived from patient’s ascites with chemoresistant
disease (9 × 105) were mixed with Matrigel (8.9 mg/mL, BD Biosciences) containing vehicle (PBS),
4-MU (1 mM), CBP (100 µM), or a combination of 4-MU (1 mM) and CBP (100 µM) and placed on
top of the CAM of day 11 chick embryos [22]. Matrigel grafts with adjacent CAM were harvested
from each embryo (n = 6–9/treatment group) after 3 days (day 14), fixed with 10% formalin for 24 h,
processed and embedded in paraffin. Serial sections (6 µm) were stained with haematoxylin and eosin
or immunostained with CD44 antibody (1/800, Clone Ab-4, 156-3C11, Thermo Scientific, Lab Vision
Corporation, Fremont, CA, USA). Immunohistochemistry was performed as described previously using
citrate buffer antigen retrieval [58]. Slides were digitally scanned using the NanoZoomer (Hamamatsu
Photonics). The area of the CD44 positive cancer cells that invaded through the ectoderm into the
mesoderm was measured using the NanoZoomer area tool. Data are expressed as CD44-positive areas
(µm2/mm2 of mesoderm).
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4.10. Statistical Analyses
All statistical analyses were performed using Graph Pad Prism 7 (version 7.02, La Jolla, CA, USA).
The Wilcoxon pair test was used to assess differences in serum HA levels in matching samples at
diagnosis and after development of recurrence. As data were not normally distributed, the Mann
Whitney U test was used to assess differences between gene expression in chemosensitive and
chemoresistant primary serous ovarian cells, and HA levels in conditioned media from primary
chemosensitive and chemoresistant serous ovarian cancer cells. The independent t test or one-way
ANOVA with Tukey’s multiple comparisons tests was used to assess differences between parental
and CBP-resistant OV-90 cells and the treatment groups in the cell survival assays. The Friedman test
with Dunn’s multiple comparison test was used to assess differences between treatment groups in
the ex-vivo explant assay. The Kruskal–Wallis test with Dunn’s multiple comparison test was used
to assess differences between the control and treatment groups for spheroid area, gene expression in
spheroids, immunostaining for ALDH1, and CAM invasion. Statistical significance was accepted at
p < 0.05.
5. Conclusions
In summary, our results show that 4-MU is effective at inhibiting the growth and invasion of
chemoresistant serous ovarian cancer cells. 4-MU is able to inhibit several HA-mediated neoplastic
properties such as proliferation and invasion by inhibiting HA production, inducing apoptosis,
and inhibiting CSC activation in chemoresistant cells. The experience in both humans and animals
to date suggests that 4-MU is safe and well tolerated [15,32,56]. Our findings suggest that 4-MU
treatment may be effective to inhibit HA production and CSC activation which occurs following
chemotherapy treatment. 4-MU treatment is therefore a promising strategy to improve survival of
patients with chemoresistant ovarian cancer and warrants further investigation in pre-clinical models
of ovarian cancer.
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